Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 39 - Medicinal preparations containing antigens or antibodies
Patents for A61K 39 - Medicinal preparations containing antigens or antibodies (182,248)
08/2010
08/31/2010US7785602 Vaccination of pigs against disease by administering a first recombinant porcine adenovirus vector stably expressing a heterologous nucleotide sequence encoding the antigenic determinant of the disease, preferably Hog Cholera Virus or Pseudorabies virus
08/31/2010US7785599 Albumin fusion proteins
08/31/2010US7785598 Alternate reading frame hepatitis C virus peptides and uses thereof
08/31/2010US7785597 generating an immune response, comprising administering to a mammal variable major protein (VMP)-like polypeptides as antigens for immunoprophylaxis, immunotherapy and immunodiagnosis; antibodies; Lyme disease
08/31/2010US7785595 Stabilized anti-hepatitis B (HBV) antibody formulations
08/31/2010US7785594 antihemophilic factor monoclonal antibodies comprising an immunoglobulin heavy chain and light chain amino acid sequences, with modified by enzymatic deglycosylation or by site directed mutagenesis, used for treating hemostasis disorders; anticoagulants
08/31/2010US7785593 Antibody (11C7) anti nogo a and its pharmaceutical use
08/31/2010US7785592 Stabilized liquid anti-RSV antibody formulations
08/31/2010US7785591 Identification and characterization of function-blocking anti-ED-B-fibronectin antibodies
08/31/2010US7785590 Monoclonal antibody against interleukin-13 receptor alpha 1 (IL-13Ra1)
08/31/2010US7785589 biological fragments comprising polypeptides, in a combination with phosphatides, used for for immunization or treatment of ischemic cardiovascular disorders, in humans
08/31/2010US7785588 Anti-neurturin receptor-A antibody compositions comprising cytokines or neurotrophic factors
08/31/2010US7785587 Mixture of corticosteroid and transforming growth factor inhibitor
08/31/2010US7785586 Capable of binding with a wild type HBsAg antigen and with at least one, preferably at least two or more, mutated forms of the HBsAg antigen
08/31/2010US7785583 administering imiquimod and carrier to a site to induce local inflammation at the site, then administering antigen-loaded antigen presenting cells, to eliciting an immune response; immunology
08/31/2010US7785571 Treatment of fungal infections
08/31/2010US7785570 Combination vaccine for poultry
08/31/2010CA2389582C Production of mammary secretion antibodies in farm animals
08/31/2010CA2217871C Altered polypeptides with increased half-life
08/31/2010CA2190371C Receptor for oncostatin m
08/26/2010WO2010096838A2 Proproteins and methods of use thereof
08/26/2010WO2010096830A2 Method to treat psoriasis and other hyperproliferative skin disorders
08/26/2010WO2010096751A1 Compositions and methods for treating a disease mediated by soluble oligomeric amyloid beta
08/26/2010WO2010096678A2 Recombinant viral vectors
08/26/2010WO2010096561A1 Synthetic hiv/siv gag proteins and uses thereof
08/26/2010WO2010096470A2 Method for inhibiting neurodegeneration
08/26/2010WO2010096418A2 Antibody molecules having specificity for human ox40
08/26/2010WO2010096289A2 Combination therapy using an anti-egfr agent(s) and igf-1r specific antibodies
08/26/2010WO2010096042A1 Mimotopes of hiv env
08/26/2010WO2010095966A1 New strain of salmonella enterica s. typhimurium, its use and a method to obtain a therapeutic vaccine vector
08/26/2010WO2010095917A1 Monoclonal antibodies against vaginolysin
08/26/2010WO2010095673A1 Cellulose gel for purification of immunoglobulin
08/26/2010WO2010095463A1 Immunopotentiating composition and process for producing same
08/26/2010WO2010095461A1 Novel monoclonal antibody, and use thereof
08/26/2010WO2010095455A1 Hypo-immunogenic streptavidin and use thereof
08/26/2010WO2010095270A1 Anti-human α9 integrin antibody and use thereof
08/26/2010WO2010094981A2 Antibody therapy
08/26/2010WO2010094970A1 Antibodies to clostridium difficile toxins
08/26/2010WO2010094906A1 The stabilisation of proteins
08/26/2010WO2010094723A2 Improved anti-serum albumin binding variants
08/26/2010WO2010094720A2 Improved anti-tnfr1 polypeptides, antibody variable domains & antagonists
08/26/2010WO2010094663A1 Inactivated dengue virus vaccine with aluminium-free adjuvant
08/26/2010WO2010094499A1 Methods and compositions for diagnosis and treatment of cancer
08/26/2010WO2010094490A1 Methods and compositions for diagnosis and treatment of cancer
08/26/2010WO2010094101A1 Vaccine composition against canine pyoderma, method of vaccinating against canine pyoderma, and use of staphylococcus intermedius toxoids
08/26/2010WO2010094068A1 Treatment of chronic inflammatory conditions
08/26/2010WO2010094064A1 Live attenuated vaccines
08/26/2010WO2010074575A3 Recombinant classical swine fever virus (csfv) comprising a modified e2 protein and methods for generating said recombinant csfv.
08/26/2010WO2010073104A3 Improving cognitive function
08/26/2010WO2010004434A3 Method of promoting neurogenesis
08/26/2010WO2009140177A3 Anti-fn14 antibodies and uses thereof
08/26/2010WO2009135614A3 Use of a virus regimen for the treatment of diseases
08/26/2010US20100218265 Immune system mediator
08/26/2010US20100217287 Self-assembling fibrous networks
08/26/2010US20100216976 Sodium-independent transporter carrying acidic amino acid and its gene
08/26/2010US20100216743 Therapy-enhancing glucan
08/26/2010US20100216716 Cell-Permeable Peptide Inhibitors Of The JNK Signal Transduction Pathway
08/26/2010US20100216714 Natriuretic compounds, conjugates, and uses thereof
08/26/2010US20100215731 Method for improving cartilage repair and/or preventing cartilage degeneration in a joint
08/26/2010US20100215729 Oligonucleotide analogues incorporating 5-aza-cytosine therein
08/26/2010US20100215728 Skincare Methods
08/26/2010US20100215727 Stabilized picoplatin dosage form
08/26/2010US20100215724 Microcapsule Nanotube Devices for Targeted Delivery of Therapeutic Molecules
08/26/2010US20100215712 Blood vessel stent of amidoglucosan polysaccharide loaded with cd133 antibody and its preparation method
08/26/2010US20100215698 Method of treating cancer cells to create a modified cancer cell that provokes an immunogenic response
08/26/2010US20100215697 Methods and materials for making and using vaccines
08/26/2010US20100215696 Efficiently replicable heptitis c virus mutant, a heptitis c virus mutant comprising reporter gene, a method of preparing of hcv vaccine using the same and a method of screening anti hcv composition using the same
08/26/2010US20100215695 Hiv preventive vaccine based on hiv specific antibodies
08/26/2010US20100215694 Infectious cDNA of North American Porcine Reproductive and Respiratory Syndrome (PRRS) Virus and Uses Thereof
08/26/2010US20100215693 Immunological herpes simplex virus antigens and methods for use thereof
08/26/2010US20100215692 Dengue Chimeric Viruses
08/26/2010US20100215691 Recombinant viral vectors
08/26/2010US20100215690 Circovirus sequences associated with piglet weight loss disease (pwd)
08/26/2010US20100215686 Process for Manufacturing Vaccines
08/26/2010US20100215685 Acyl pseudodipeptides which carry a functionalized auxiliary arm
08/26/2010US20100215684 Streptococcus m protein, immunogenic fragments, nucleic acids and methods of use
08/26/2010US20100215683 Protective antigens for group b streptococcus hypervirulent strains
08/26/2010US20100215682 Deletion of the beta 20-21 loop in hiv gp120 exposes the cd4 binding site for improved antibody binding and antibody induction
08/26/2010US20100215681 Fusion proteins comprising hiv-1 tat and/or nef proteins
08/26/2010US20100215680 Replikin peptides and antibodies therefor
08/26/2010US20100215679 Methods and compositions for treating tularemia
08/26/2010US20100215678 Ras Mutation and Compositions and Methods Related Thereto
08/26/2010US20100215677 Pdz domain interactions and lipid rafts
08/26/2010US20100215676 Kdr peptides and vaccines comprising the same
08/26/2010US20100215675 Replikin-based compounds for prevention and treatment of influenza and methods of differentiating infectivity and lethality in influenza
08/26/2010US20100215674 Enhancing the t-cells stimulatory capacity of human antigen presenting cells and their use in vaccination
08/26/2010US20100215673 Method for treating inflammation and controlled-release material capable of providing same
08/26/2010US20100215672 Preparation process and utilization of Poncirus compositions having anti-allergic and antianaphylactic properties
08/26/2010US20100215671 Combination Therapy With Antibody-Drug Conjugates
08/26/2010US20100215670 Immunotoxin Fusions Comprising An Antibody Fragment and a Plant Toxin Linked by Protease Cleavable Linkers
08/26/2010US20100215669 Anti-cd79b antibodies and immunoconjugates and methods of use
08/26/2010US20100215668 Methods for the treatment or prevention of hemorrhagic conditions
08/26/2010US20100215667 Methods and compositions of treatment for modulating the immune system of animals
08/26/2010US20100215666 Il-17 antagonistic antibodies
08/26/2010US20100215665 Mixed lineage kinases and metabolic disorders
08/26/2010US20100215664 Amino acid sequences directed against il-6r and polypeptides comprising the same for the treatment of diseases and disorders associated with il-6 -mediated signalling
08/26/2010US20100215663 Methods and compositions for regulation of neurological conditions
08/26/2010US20100215662 Anti-influenza M2e antibody
08/26/2010US20100215661 Nicotinamide derivates useful as p38 inhibitors
08/26/2010US20100215660 Kruppel-like factors and fat regulation
1 ... 498 499 500 501 502 503 504 505 506 507 508 509 510 511 512 513 514 515 516 517 518 ... 1823